Inactive Instrument

Akers Biosciences Inc Stock Nasdaq

Equities

US00973E1029

Sales 2022 - Sales 2023 - Capitalization 13.17M
Net income 2022 -15M Net income 2023 -4M EV / Sales 2022 -
Net cash position 2022 4.69M Net cash position 2023 4.87M EV / Sales 2023 -
P/E ratio 2022
-2.94 x
P/E ratio 2023
-1.46 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data MT
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell MT
Top Premarket Gainers MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement MT
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split MT
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis CI
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain CI
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023 CI
MyMD Pharmaceuticals, Inc.(NasdaqCM:MYMD) dropped from S&P Global BMI Index CI
Insider Buy: Mymd Pharmaceuticals MT
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
MyMD Pharmaceuticals Says Its Investigational New Drug Application for Rheumatoid Arthritis Treatment Gets FDA Acceptance MT
FDA Accepts MyMD Pharmaceuticals, Inc. Investigational New Drug Application for Phase 2 Study of Oral Tnf-A Inhibitor Mymd-1®? in Rheumatoid Arthritis CI
More news
Managers TitleAgeSince
Chief Executive Officer 58 17-08-07
Director of Finance/CFO 51 21-01-28
- -
Members of the board TitleAgeSince
Chief Executive Officer 58 17-08-07
71 -
Chairman 53 18-09-05
More insiders
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company's product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
Sector
-
More about the company